Odesivimab-ebgn

Odesivimab-ebgn Uses, Dosage, Side Effects, Food Interaction and all others data.

Ebola virus (EBOV) remains an important human pathogen within the Ebolavirus genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high specificity. The chief surface target of EBOV particles is the GP1,2 glycoprotein, which also appears on the surface of EBOV-infected cells, offering opportunities for both neutralizing and cytotoxic (i.e. through Fc-mediated immune effector function) antibody effects to play a role in combatting EBOV infection. A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.

INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1κ mAbs Odesivimab-ebgn (REGN 3471), Maftivimab (REGN 3479), and Atoltivimab (REGN 3470) in equimolar proportions. All three mAbs bind to a distinct portion of the GP1,2 glycoprotein and collectively provide neutralizing and Fc-mediated immune effector function against EBOV in vitro and protection against EBOV infection in vivo. INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.

Odesivimab-ebgn is a fully-humanized IgG1κ monoclonal antibody (mAb) directed against the GP1,2 glycoprotein that provides both neutralizing and Fc-dependent immune-mediated activity against Zaire ebolavirus. As a mAb, Odesivimab-ebgn exhibits low toxicity and is generally well tolerated but does include the risk of potentially life-threatening hypersensitivity reactions.

Odesivimab-ebgn
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Odesivimab-ebgn
Generic	Odesivimab
Odesivimab Other Names	Odesivimab, odesivimab-ebgn
Type
Formula	C₆₅₀₆H₁₀₀₂₄N₁₇₂₀O₂₀₃₀S₄₂
Weight	146164.54 Da (Polypeptide only)
Groups	Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Odesivimab-ebgn is part of a product containing three monoclonal IgG1κ antibodies directed against the GP<sub>1,2</sub> glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.

Odesivimab-ebgn is indicated in combination with Maftivimab and Atoltivimab for the treatment of Zaire ebolavirus infection in adult and pediatric patients, including neonates born to a mother who has been confirmed positive by RT-PCR for Zaire ebolavirus infection. This combination has not been established as efficacious for any other species within either the Ebolavirus or Marburgvirus genera; special care should be taken to evaluate the susceptibility of circulating Zaire ebolavirus strains before beginning treatment, and the possible emergence of resistance should be monitored.

Odesivimab-ebgn is also used to associated treatment for these conditions: Ebola Virus Infection

How Odesivimab-ebgn works

Ebola virus (EBOV) is one of several viruses within the Ebolavirus genus known to infect humans with an average case fatality rate of 43.92%. EBOV particles expose the GP_1,2 glycoprotein on their surface, which comprises a trimer of GP₁ and GP₂ subunit heterodimers, with the subunits connected by a disulfide bond. GP_1,2 plays an important role in both cell surface attachment/entry and eventual lysosomal escape through binding to the NPC intracellular cholesterol transporter 1/Niemann-Pick C1 protein (NPC1). In this manner, GP_1,2 is integral to the pathogenic cycle of EBOV.

Odesivimab-ebgn is a fully-humanized IgG1κ monoclonal antibody (mAb) directed against the EBOV GP_1,2 glycoprotein, which binds within the "chalice" structure near the GP head in partial contact with the glycan cap with a binding affinity (K_D) of between 8.26 and 8.42 nM. Odesivimab-ebgn exhibits weak (1,2 and is able to bind soluble GP_1,2. In addition, Odesivimab-ebgn is capable of dose-dependent activation of FcγRIIIa signalling in effector cells in the presence of GP_1,2-expressing cells with a half-maximal effective concentration (EC₅₀) of 1.6 nM. Combined with Maftivimab and Atoltivimab, Odesivimab-ebgn works to block EBOV cell infection and lysosomal escape, as well as the potential antibody-dependent cell-mediated killing of EBOV-infected cells.